Meijboom, KE, Volpato, V, Monzón-Sandoval, J, Hoolachan, JM, Hammond, SM, Abendroth, F, de Jong, OG, Hazell, G, Ahlskog, N, Wood, MJA, Webber, C and Bowerman, M (2021) Combining multi-omics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI Insight, 6 (13). pp. 1-24. ISSN 2379-3708

[thumbnail of Clean Copy - No changes indicated.pdf]
Clean Copy - No changes indicated.pdf - Accepted Version

Download (2MB) | Preview
[thumbnail of © 2021, Meijboom et al.pdf]
© 2021, Meijboom et al.pdf - Published Version

Download (9MB) | Preview


Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss of survival motor neuron (SMN) protein. While SMN restoration therapies are beneficial, they are not a cure. We aimed to identify novel treatments to alleviate muscle pathology combining transcriptomics, proteomics and perturbational datasets. This revealed potential drug candidates for repurposing in SMA. One of the candidates, harmine, was further investigated in cell and animal models, improving multiple disease phenotypes, including lifespan, weight and key molecular networks in skeletal muscle. Our work highlights the potential of multiple and parallel data driven approaches for the development of novel treatments for use in combination with SMN restoration therapies.

Item Type: Article
Additional Information: © 2021, Meijboom et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Subjects: R Medicine > R Medicine (General)
R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Medicine and Health Sciences > School of Medicine
Depositing User: Symplectic
Date Deposited: 19 May 2021 09:01
Last Modified: 21 Sep 2021 15:02

Actions (login required)

View Item
View Item